Literature DB >> 20045267

External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity.

Kiran Devisetty1, Kevin C Zorn, Mark H Katz, Ashesh B Jani, Stanley L Liauw.   

Abstract

PURPOSE: To describe genitourinary (GU) toxicity in men with a history of transurethral resection of the prostate (TURP) treated with external beam radiation therapy (EBRT) for prostate cancer. METHODS AND MATERIALS: Seventy-one men with a history of TURP were treated with EBRT for prostate cancer. The median time from TURP to EBRT was 15 months. The median EBRT dose was 70 Gy, and 21 men (30%) received androgen deprivation therapy (ADT). Acute GU toxicity and late GU toxicity were scored by Radiation Therapy Oncology Group criteria and compared with a cohort of 538 men without prior TURP. The median follow-up for men with TURP and men without TURP was 40 months and 50 months, respectively (p = 0.7605).
RESULTS: The rate of acute Grade 2 GU toxicity or higher was 41%, and was increased with a history of more than 1 TURP (73% vs. 31%, p = 0.0036). The 4-year rate of freedom from late Grade 3 GU toxicity or higher was 84%, and was decreased with ADT (45% vs. 95% without ADT, p = 0.0024). By last follow-up, maximal GU toxicity tended to resolve (p < 0.0001) and there was no worsening of urinary symptom scores (p = 0.6911). Compared to men without a prior TURP, TURP patients had a lower rate of freedom from late Grade 3 toxicity or higher (84% vs. 96%, p = 0.0483). Multivariate analysis suggested a higher rate of late Grade 3 toxicity or higher with TURP (risk ratio, 2.87; p = 0.0612) and EBRT dose of 74 Gy or greater (risk ratio, 2.26; p = 0.0521).
CONCLUSIONS: Men treated for prostate cancer with EBRT after TURP have a higher risk of severe GU toxicity; however, the overall incidence is low, and toxicity tends not to persist. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20045267     DOI: 10.1016/j.ijrobp.2009.06.078

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer.

Authors:  Sarah L Kerns; Ashley Amidon Morlang; Sharon M Lee; Derick R Peterson; Brian Marples; Hong Zhang; Kevin Bylund; Doug Rosenzweig; William Hall; Kim De Ruyck; Barry S Rosenstein; Richard G Stock; Antonio Gómez-Caamaño; Ana Vega; Paloma Sosa-Fajardo; Begoña Taboada-Valladares; Miguel E Aguado-Barrera; Chris Parker; Liv Veldeman; Valérie Fonteyne; Renée Bultijnck; Christopher J Talbot; R Paul Symonds; Kerstie Johnson; Tim Rattay; Adam Webb; Maarten Lambrecht; Dirk de Ruysscher; Ben Vanneste; Ananya Choudhury; Rebecca M Elliott; Elena Sperk; Carsten Herskind; Marlon R Veldwijk; Tiziana Rancati; Barbara Avuzzi; Riccardo Valdagni; David Azria; Marie-Pierre Farcy Jacquet; Jenny Chang-Claude; Petra Seibold; Catharine West; Michelle Janelsins; Yuhchyau Chen; Edward Messing; Gary Morrow
Journal:  Radiother Oncol       Date:  2022-01-22       Impact factor: 6.280

2.  Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.

Authors:  Marie K Gurka; Leonard N Chen; Aditi Bhagat; Rudy Moures; Joy S Kim; Thomas Yung; Siyuan Lei; Brian T Collins; Pranay Krishnan; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Radiat Oncol       Date:  2015-02-19       Impact factor: 3.481

3.  Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer.

Authors:  Jennifer A Woo; Leonard N Chen; Aditi Bhagat; Eric K Oermann; Joy S Kim; Rudy Moures; Thomas Yung; Siyuan Lei; Brian T Collins; Deepak Kumar; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Front Oncol       Date:  2014-05-26       Impact factor: 6.244

4.  Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).

Authors:  Abigail Pepin; Nima Aghdam; Sarthak Shah; Shaan Kataria; Harry Tsou; Subhradeep Datta; Malika Danner; Marilyn Ayoob; Thomas Yung; Siyuan Lei; Marie Gurka; Brian T Collins; Pranay Krishnan; Simeng Suy; Ryan Hankins; John H Lynch; Sean P Collins
Journal:  Front Oncol       Date:  2020-05-05       Impact factor: 6.244

5.  Patient-Reported Quality of Life in Men with Transurethral Resection of the Prostate Undergoing Proton Therapy for Management of Prostate Cancer.

Authors:  Derek T Lee; Nancy P Mendenhall; Tamara L Smith; Christopher G Morris; Romaine C Nichols; Curtis Bryant; Randal H Henderson; William M Mendenhall; Joseph Costa; Christopher R Williams; Zuofeng Li; Bradford S Hoppe
Journal:  Int J Part Ther       Date:  2016

6.  Morbidity dynamics in proton-photon or photon radiation therapy for locally advanced prostate cancer.

Authors:  Evgeny V Khmelevsky; Irina N Kancheli; Vladimir S Khoroshkov; Andrey D Kaprin
Journal:  Rep Pract Oncol Radiother       Date:  2017-11-24

7.  Gross hematuria in patients with prostate cancer: etiology and management.

Authors:  Ofer N Gofrit; Ran Katz; Amos Shapiro; Vladimir Yutkin; Galina Pizov; Kevin C Zorn; Mordechai Duvdevani; Ezekiel H Landau; Dov Pode
Journal:  ISRN Surg       Date:  2013-03-24

8.  Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials.

Authors:  Randal H Henderson; Bradford S Hoppe; Robert B Marcus; William M Mendenhall; R Charles Nichols; Zuofeng Li; Zhong Su; Christopher G Morris; Christopher R Williams; Joseph Costa; Nancy P Mendenhall
Journal:  Acta Oncol       Date:  2013-04       Impact factor: 4.089

9.  Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.

Authors:  W Tristram Arscott; Leonard N Chen; Nathan Wilson; Aditi Bhagat; Joy S Kim; Rudy A Moures; Thomas M Yung; Siyuan Lei; Brian T Collins; Keith Kowalczyk; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Radiat Oncol       Date:  2014-07-24       Impact factor: 3.481

10.  Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasia.

Authors:  Mélanie Guilhen; Christophe Hennequin; Idir Ouzaid; Ingrid Fumagalli; Valentine Martin; Sophie Guillerm; Pierre Mongiat-Artus; Vincent Ravery; François Desgrandchamps; Laurent Quéro
Journal:  Radiat Oncol       Date:  2018-10-24       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.